The following Gulf countries (UAE, Oman, Bahrain, Qatar and Kuwait) authorizations are based on
the Local Regulatory
Authorities' Emergency Use Authorization for PAXLOVID
Tablet core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal
silicon dioxide, sodium stearyl fumarate. Film-coat:hydroxy propyl methylcellulose (E464),
titanium dioxide (E171), polyethylene glycol (E1521), iron oxide red (E172).
Tablet core: copovidone, sorbitan laureate, silica, colloidal anhydrous, calcium hydrogen
phosphate, anhydrous, sodium stearyl fumarate. Film-coat: hypromellose (E464), titanium dioxide
(E171), macrogol, hydroxypropyl cellulose (E463), talc (E553b), silica, colloidal anhydrous
(E551), polysorbate 80 (E433).
For information regarding other allergen/ingredients, please contact Medical Information at
contact our Medical Information team on
Each Nirmatrelvir 150 mg film-coated tablet contains 176 mg of lactose. Patients
with rare hereditary problems of galactose intolerance, total lactase deficiency or
glucose-galactose malabsorption should not take this medicine.
We cannot guarantee that minute amounts of substances are not contained in raw materials obtained
from our suppliers. To ensure we have a consistent and reliable supply of medications, we must use
a network of suppliers and manufacturing sites globally for both active and inactive
Nirmatrelvir and ritonavir each contain less than 1 mmol sodium (23 mg) per dose, that is to say
essentially ‘sodium free’.
Ritonavir is administered with Nirmatrelvir as a pharmacokinetic enhancer resulting in higher
systemic concentrations of Nirmatrelvir.
Ritonavir is not active against the SARS-CoV-2 3CL protease. Ritonavir inhibits the
CYP3A-mediated metabolism of Nirmatrelvir, thereby providing increased plasma concentrations of
In healthy participants, the mean half-life of a single dose of 150 mg Nirmatrelvir administered
alone was approximately 2 hours compared to 7.5 hours after administration of a single dose of 250
mg/100 mg dose of Nirmatrelvir/ritonavir thereby supporting a twice‑daily administration
Submit your medical enquiry on a Pfizer medicine.
In the event of a suspected adverse event or side effect with no associated medical information enquiry, please contact
[email protected]. Please always specify your country (i.e. Bahrain, Kuwait, Qatar, Oman, UAE.). If you have a medical information enquiry including those with associated adverse events, contact Medical Information.